501 related articles for article (PubMed ID: 33757970)
1. Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance.
Tan SK; Mahmud I; Fontanesi F; Puchowicz M; Neumann CKA; Griswold AJ; Patel R; Dispagna M; Ahmed HH; Gonzalgo ML; Brown JM; Garrett TJ; Welford SM
Cancer Discov; 2021 Aug; 11(8):2072-2093. PubMed ID: 33757970
[TBL] [Abstract][Full Text] [Related]
2. Chemerin Tips the Scales in ccRCC to Evade Ferroptosis.
Reznik E; Jiang H; Hakimi AA
Cancer Discov; 2021 Aug; 11(8):1879-1880. PubMed ID: 34344758
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
4. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma.
Miess H; Dankworth B; Gouw AM; Rosenfeldt M; Schmitz W; Jiang M; Saunders B; Howell M; Downward J; Felsher DW; Peck B; Schulze A
Oncogene; 2018 Oct; 37(40):5435-5450. PubMed ID: 29872221
[TBL] [Abstract][Full Text] [Related]
5. Fatty Acid Oxidation Mediated by Malonyl-CoA Decarboxylase Represses Renal Cell Carcinoma Progression.
Zhou L; Luo Y; Liu Y; Zeng Y; Tong J; Li M; Hou Y; Du K; Qi Y; Pan W; Liu Y; Wang R; Tian F; Gu C; Chen K
Cancer Res; 2023 Dec; 83(23):3920-3939. PubMed ID: 37729394
[TBL] [Abstract][Full Text] [Related]
6. Lipid in Renal Carcinoma: Queen Bee to Target?
Tan SK; Welford SM
Trends Cancer; 2020 Jun; 6(6):448-450. PubMed ID: 32459999
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of the X-inactivation escaping gene
Zheng Q; Li P; Zhou X; Qiang Y; Fan J; Lin Y; Chen Y; Guo J; Wang F; Xue H; Xiong J; Li F
Theranostics; 2021; 11(18):8674-8691. PubMed ID: 34522206
[No Abstract] [Full Text] [Related]
8. HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation.
Han S; Lin F; Qi Y; Liu C; Zhou L; Xia Y; Chen K; Xing J; Liu Z; Yu W; Zhang Y; Zhou X; Rao T; Cheng F
Oxid Med Cell Longev; 2022; 2022():3846217. PubMed ID: 35656025
[TBL] [Abstract][Full Text] [Related]
9. Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1.
Zhu L; Huang J; Wang Y; Yang Z; Chen X
Life Sci; 2021 Aug; 278():119530. PubMed ID: 33887347
[TBL] [Abstract][Full Text] [Related]
10. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
11. ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma.
Klasson TD; LaGory EL; Zhao H; Huynh SK; Papandreou I; Moon EJ; Giaccia AJ
Cancer Metab; 2022 Oct; 10(1):14. PubMed ID: 36192773
[TBL] [Abstract][Full Text] [Related]
12. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment-Responsive Nanodrug for Clear-Cell Renal Cell Carcinoma Therapy via Triggering Waterfall-Like Cascade Ferroptosis.
Ni W; Li Y; Liang L; Yang S; Zhan M; Lu C; Lu L; Wen L
J Biomed Nanotechnol; 2022 Feb; 18(2):327-342. PubMed ID: 35484753
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.
Tan SK; Hougen HY; Merchan JR; Gonzalgo ML; Welford SM
Nat Rev Urol; 2023 Jan; 20(1):48-60. PubMed ID: 36192502
[TBL] [Abstract][Full Text] [Related]
15. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
16. GPR1 and CMKLR1 control lipid metabolism to support development of clear cell renal cell carcinoma.
Wang D; Mahmud I; Thakur VS; Tan SK; Isom DG; Lombard DB; Gonzalgo ML; Kryvenko ON; Lorenzi PL; Tcheuyap VT; Brugarolas J; Welford SM
Cancer Res; 2024 Apr; ():. PubMed ID: 38640229
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
18. Targeting lipid biosynthesis on the basis of conventional treatments for clear cell renal cell carcinoma: A promising therapeutic approach.
Guo T; Zhang X; Chen S; Wang X; Wang X
Life Sci; 2024 Jan; 336():122329. PubMed ID: 38052321
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high
Miikkulainen P; Högel H; Seyednasrollah F; Rantanen K; Elo LL; Jaakkola PM
J Biol Chem; 2019 Mar; 294(10):3760-3771. PubMed ID: 30617181
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
